FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alex Sparreboom

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Eric I Zimmerman; AA Gibson; Shuiying Hu; Lie Li; Shelley J Orwick; Justin L Roberts; Alex Sparreboom; Sharyn D Baker
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
C D Drenberg; Sharyn D Baker; Alex Sparreboom
Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
Ron H J Mathijssen; Peter de Bruijn; Karel Eechoute; Alex Sparreboom
Long-term prospective population PK study in GIST patients--response.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alex Sparreboom (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Eric I Zimmerman; AA Gibson; Shuiying Hu; Lie Li; Shelley J Orwick; Justin L Roberts; Alex Sparreboom; Sharyn D Baker
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(6):1458-66.
2013: C D Drenberg; Sharyn D Baker; Alex Sparreboom
Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
Clinical pharmacology and therapeutics 2013;93(3):215-9.
2013: Ron H J Mathijssen; Peter de Bruijn; Karel Eechoute; Alex Sparreboom
Long-term prospective population PK study in GIST patients--response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(4):950.
2013: Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Polymorphic transporters and platinum pharmacodynamics.
Drug metabolism and pharmacokinetics 2013;28(1):19-27.
2012: J A Sprowl; Alex Sparreboom
Drug trafficking: recent advances in therapeutics and disease.
Clinical pharmacology and therapeutics 2012;92(5):531-4.
2012: Karel Eechoute; Martin N Fransson; Lena E Friberg; Walter J Loos; Ron H J Mathijssen; A K L Reyners; Gaia Schiavon; Alex Sparreboom; Winette T A van der Graaf; Jaap Verweij; Erik A C Wiemer; Floris A de Jong; Ugo De Giorgi
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(20):5780-7.
2012: Etienne Chatelut; Ron H J Mathijssen; Florent Puisset; S D Baker; M L White-Koning; Alex Sparreboom
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
British journal of cancer 2012;107(7):1100-6.
2012: Anne-Joy M de Graan; Guoqing Du; Laure Elens; Lena E Friberg; Alice A Gibson; Bruno Hagenbuch; Shuiying Hu; Cynthia S Lancaster; Walter J Loos; Ron H J Mathijssen; Torben S Mikkelsen; Amanda Obaidat; Sharyn D Baker; Gitte H Bruun; Thomas J Corydon; Peter de Bruijn; Ron H N van Schaik; Aisha L Walker; Alex Sparreboom
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4433-40.
2012: J A Sprowl; Vanesa Gregorc; C Lazzari; Walter J Loos; Ron H J Mathijssen; Alex Sparreboom
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.
Clinical pharmacology and therapeutics 2012;91(6):1022-6.
2012: Jennifer J Griggs; William M Hryniuk; Gary H Lyman; Pamela B Mangu; Vicki A Morrison; T May Pini; Gary Rosner; Carolyn D Runowicz; Michelle Shayne; Alex Sparreboom; Lara E Sucheston; Holly Anderson; Edward P Balaban; James J Dignam
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(13):1553-61.
2012: Chaoxin Hu; Shuiying Hu; Cynthia S Lancaster; Jeffrey E Rubnitz; Sharyn D Baker; Zhaoyuan Chen; Zhili Zuo; Alex Sparreboom
Inhibition of OCTN2-mediated transport of carnitine by etoposide.
Molecular cancer therapeutics 2012;11(4):921-9.
2012: Giuliano Ciarimboli; Ryan M Franke; Denise Guckel; Edwin Herrmann; Cynthia S Lancaster; Vivian Massmann; Ron H J Mathijssen; Hermann Pavenstädt; Ching-Hon Pui; Mary V Relling; Eberhard Schlatter; Jason A Sprowl; Wenjian Yang; Alex Sparreboom
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1101-8.
2012: Jason A Sprowl; Hugh Giovinazzo; Torben S Mikkelsen; Alex Sparreboom
Contribution of tumoral and host solute carriers to clinical drug response.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2012;15(1-2):5-20.
2011: Russell E Ware; Song Wu; Banu Aygun; Jenny M Despotovic; Jonathan M Flanagan; Jin He; Thad Howard; Amy C Kimble; Nicole A Mortier; Matthew P Smeltzer; Alex Sparreboom
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
Blood 2011;118(18):4985-91.
2011: K Eechoute; R M Franke; Walter J Loos; L A Scherkenbach; I Boere; Jaap Verweij; H Gurney; R B Kim; R G Tirona; Ron H J Mathijssen; Alex Sparreboom
Environmental and genetic factors affecting transport of imatinib by OATP1A2.
Clinical pharmacology and therapeutics 2011;89(6):816-20.
2011: Ryan Franke; C S Lancaster; C J Peer; A A Gibson; A M Kosloske; S J Orwick; Ron H J Mathijssen; W D Figg; Sharyn D Baker; Alex Sparreboom
Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.
Clinical pharmacology and therapeutics 2011;89(5):693-701.
2011: Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1771-8.
2011: C S Lancaster; Alex Sparreboom
Pharmaceutical relevance of drug transporter malfunctions.
Clinical pharmacology and therapeutics 2011;89(4):471-4.
2011: Aisha L Walker; Ryan M Franke; Alex Sparreboom; Russell E Ware
Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters.
Experimental hematology 2011;39(4):446-56.
2011: Shinjiro Nagai; Kazumasa Takenaka; Deepa Nachagari; Charles Rose; Kali Domoney; Daxi Sun; Alex Sparreboom; John D Schuetz
Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.
Cancer research 2011;71(5):1781-91.
2011: Tristan Sissung; Erin R Gardner; Richard L Piekarz; Reuben Howden; Xiaohong Chen; Sukyung Woo; Ryan Franke; James A Clark; Laura Miller-DeGraff; Seth M Steinberg; David Venzon; David J Liewehr; Steven R Kleeberger; Susan E Bates; Douglas K Price; Douglas R Rosing; Christopher Cabell; Alex Sparreboom; William D Figg
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):937-46.
2011: Karel Eechoute; Alex Sparreboom; Herman Burger; Ryan M Franke; Gaia Schiavon; Jaap Verweij; Walter J Loos; Erik A C Wiemer; Ron H J Mathijssen
Drug transporters and imatinib treatment: implications for clinical practice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(3):406-15.
2010: Nicola F Smith; Sridhar Mani; Erin G Schuetz; Kazuto Yasuda; Tristan M Sissung; Susan E Bates; William D Figg; Alex Sparreboom
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
The Annals of pharmacotherapy 2010;44(11):1709-17.
2010: Ryan M Franke; Michael A Carducci; MICHELLE RUDEK-RENAUT; Sharyn D Baker; Alex Sparreboom
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4562-7.
2010: Cynthia S Lancaster; Chaoxin Hu; Ryan M Franke; Kelly K Filipski; Shelley J Orwick; Zhaoyuan Chen; Zhili Zuo; Walter J Loos; Alex Sparreboom
Cisplatin-induced downregulation of OCTN2 affects carnitine wasting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4789-99.
2010: Ryan M Franke; Ashley M Kosloske; Cynthia S Lancaster; Kelly K Filipski; Chaoxin Hu; Oliver Zolk; Ron H J Mathijssen; Alex Sparreboom
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(16):4198-206.
2010: Ken-ichi Fujita; Alex Sparreboom
Pharmacogenetics of irinotecan disposition and toxicity: a review.
Current clinical pharmacology 2010;5(3):209-17.
2010: Jessica M van der Bol; Ron H J Mathijssen; Geert-Jan M Creemers; A S T Planting; Walter J Loos; Erik A C Wiemer; Lena E Friberg; Jaap Verweij; Alex Sparreboom; Floris A de Jong
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):736-42.
2010: John C Panetta; Alex Sparreboom; Ching-Hon Pui; Mary V Relling; William E Evans
Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
PLoS computational biology 2010;6(12):e1001019.
2010: Jessica van der Bol; Floris A de Jong; Ron van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; P L A van Daele; Jaap Verweij; Stefan Sleijfer; Ron H J Mathijssen
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
The oncologist 2010;15(10):1063-72.
2009: Lisa R Treviño; Noriko Shimasaki; Wenjian Yang; John C Panetta; Cheng Cheng; Deqing Pei; Diana Chan; Alex Sparreboom; Kathleen M Giacomini; Ching-Hon Pui; William Evans; Mary Relling
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):5972-8.
2009: Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; MICHELLE RUDEK-RENAUT; Alex Sparreboom; Sharyn D Baker
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6062-9.
2009: K K Filipski; R H Mathijssen; T S Mikkelsen; A H Schinkel; Alex Sparreboom
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
Clinical pharmacology and therapeutics 2009;86(4):396-402.
2009: Ryan Franke; Lisa A Scherkenbach; Alex Sparreboom
Pharmacogenetics of the organic anion transporting polypeptide 1A2.
Pharmacogenomics 2009;10(3):339-44.
2009: Alex Sparreboom; Jaap Verweij
Advances in cancer therapeutics.
Clinical pharmacology and therapeutics 2009;85(2):113-7.
2009: S D Baker; Jaap Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; Ryan Franke; S Hu; E G Schuetz; Vishal Lamba; Wells A Messersmith; Antonio C Wolff; Michael A Carducci; Alex Sparreboom
Pharmacogenetic pathway analysis of docetaxel elimination.
Clinical pharmacology and therapeutics 2009;85(2):155-63.
2009: Erin R Gardner; Nicola F Smith; William D Figg; Alex Sparreboom
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
Journal of experimental & clinical cancer research : CR 2009;28():99.
2009: R H J Mathijssen; Alex Sparreboom
Influence of lean body weight on anticancer drug clearance.
Clinical pharmacology and therapeutics 2009;85(1):23; author reply 24.
2008: Ryan Franke; S D Baker; R H Mathijssen; E G Schuetz; Alex Sparreboom
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Clinical pharmacology and therapeutics 2008;84(6):704-9.
2008: Ryan Franke; Alex Sparreboom
Inhibition of imatinib transport by uremic toxins during renal failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4226-7; author reply 4227-8.
2008: F A de Jong; J Verweij; Alex Sparreboom
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(5):1152.
2008: George Cusatis; Alex Sparreboom
Pharmacogenomic importance of ABCG2.
Pharmacogenomics 2008;9(8):1005-9.
2008: Floris A de Jong; Jessica van der Bol; Ron H J Mathijssen; Teun van Gelder; Erik A C Wiemer; Alex Sparreboom; Jaap Verweij
Renal function as a predictor of irinotecan-induced neutropenia.
Clinical pharmacology and therapeutics 2008;84(2):254-62.
2008: Tristan Sissung; Caitlin E Baum; John Deeken; Douglas K Price; Jeanny Aragon-Ching; Seth M Steinberg; William Dahut; Alex Sparreboom; William D Figg
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4543-9.
2008: Erin R Gardner; William L Dahut; Charity D Scripture; Jacquin Jones; Jeanny B Aragon-Ching; Neil Desai; Michael J Hawkins; Alex Sparreboom; William D Figg
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4200-5.
2008: Kelly K Filipski; Walter J Loos; Jaap Verweij; Alex Sparreboom
Interaction of Cisplatin with the human organic cation transporter 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3875-80.
2008: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3312-8.
2008: Nicola F Smith; Sharyn D Baker; Frank J Gonzalez; J W Harris; William D Figg; Alex Sparreboom
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
British journal of cancer 2008;98(10):1630-2.
2008: Shuiying Hu; Ryan Franke; Kelly K Filipski; Chaoxin Hu; Shelley J Orwick; Ernst A de Bruijn; Herman Burger; Sharyn D Baker; Alex Sparreboom
Interaction of imatinib with human organic ion carriers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3141-8.
2008: Balasubramanian Poonkuzhali; Jatinder Lamba; Stephen Strom; Alex Sparreboom; Kenneth E Thummel; Paul B Watkins; Erin G Schuetz
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(4):780-95.
2008: Zyting Chu; Jen-Shi Chen; Chi-Ting Liau; Hung-Ming Wang; Yung-Chang Lin; Muh-Hwa Yang; Po-Min Chen; Erin R Gardner; William D Figg; Alex Sparreboom
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
Anti-cancer drugs 2008;19(3):275-81.
2008: Erin R Gardner; Alex Sparreboom; Jaap Verweij; William D Figg
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.
Cancer biology & therapy 2008;7(3):412-5.
2008: Vanesa Gregorc; Manuel Hidalgo; Anna Spreafico; George Cusatis; Vienna Ludovini; Roxann G Ingersoll; S Marsh; S M Steinberg; M G Viganò; D Ghio; Eugenio Villa; Alex Sparreboom; Sharyn D Baker
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Clinical pharmacology and therapeutics 2008;83(3):477-84.
2008: Floris A de Jong; Alex Sparreboom; Jaap Verweij; Ron H J Mathijssen
Lifestyle habits as a contributor to anti-cancer treatment failure.
European journal of cancer (Oxford, England : 1990) 2008;44(3):374-82.
2008: Tristan Sissung; Romano Danesi; Douglas K Price; Seth M Steinberg; Ronald de Wit; Muhammad Zahid; Nilesh Gaikwad; Ercole Cavalieri; William L Dahut; Dan L Sackett; William D Figg; Alex Sparreboom
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Molecular cancer therapeutics 2008;7(1):19-26.
2008: David S Schrump; Maria R Fischette; Dao Nguyen; Ming Zhao; Xinmin Li; Tricia F Kunst; Ana Hancox; Julie A Hong; G Aaron Chen; Evgeny Kruchin; John J Wright; Douglas R Rosing; Alex Sparreboom; William D Figg; Seth M Steinberg
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):188-98.
2007: Nielka P H van Erp; Hans Gelderblom; Mats O Karlsson; Jing Li; Ming Zhao; Jan Ouwerkerk; J W R Nortier; Henk-Jan Guchelaar; Sharyn D Baker; Alex Sparreboom
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7394-400.
2007: Alex Sparreboom; Antonio C Wolff; Ron H J Mathijssen; Etienne Chatelut; Eric K Rowinsky; Jaap Verweij; Sharyn D Baker
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4707-13.
2007: Akinobu Hamada; Romano Danesi; Douglas K Price; Tristan Sissung; Cindy Chau; David Venzon; Alex Sparreboom; William L Dahut; William D Figg
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology 2007;70(2):217-20.
2007: Ron H J Mathijssen; Floris A de Jong; Walter J Loos; Jessica van der Bol; Jaap Verweij; Alex Sparreboom
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
The oncologist 2007;12(8):913-23.
2007: Alex Sparreboom
Unexplored pharmacokinetic opportunities with microdosing in oncology.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4033-4.
2007: Jessica van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron van Schaik; M J A de Jonge; A S T Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
2007: Nehal J Lakhani; Alex Sparreboom; Xia Xu; Timothy D Veenstra; Jürgen Venitz; William L Dahut; William D Figg
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Journal of pharmaceutical sciences 2007;96(7):1821-31.
2007: Florent Puisset; Etienne Chatelut; Alex Sparreboom; Jean-Pierre Delord; D Berchery; Isabelle Lochon; Thierry Lafont; Henri Roché
Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.
Cancer chemotherapy and pharmacology 2007;60(2):305-8.
2007: Ivana Gojo; Anchalee Jiemjit; Jane Trepel; Alex Sparreboom; William D Figg; Sandra Rollins; Michael L Tidwell; Jacqueline Greer; Eun Joo Chung; Min-Jung Lee; Steven D Gore; Edward A Sausville; James Zwiebel; Judith E Karp
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
2007: Frederike K Engels; Floris A de Jong; Alex Sparreboom; Ron A A Mathot; Walter J Loos; Jos J E M Kitzen; Peter de Bruijn; Jaap Verweij; Ron H J Mathijssen
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
The oncologist 2007;12(3):291-300.
2007: Jing Li; George Cusatis; Julie R Brahmer; Alex Sparreboom; Robert W Robey; Susan E Bates; Manuel Hidalgo; Sharyn D Baker
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Cancer biology & therapy 2007;6(3):432-8.
2007: John F Deeken; William D Figg; Susan E Bates; Alex Sparreboom
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Anti-cancer drugs 2007;18(2):111-26.
2007: Nicola F Smith; Sharon Marsh; Tiffany J Scott-Horton; A Hamada; Stephan Mielke; Klaus Mross; William D Figg; Jaap Verweij; howard mcleod; Alex Sparreboom
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Clinical pharmacology and therapeutics 2007;81(1):76-82.
2007: Floris A de Jong; Tiffany J Scott-Horton; D L Kroetz; howard mcleod; Lena E Friberg; Ron H J Mathijssen; Jaap Verweij; Sharon Marsh; Alex Sparreboom
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Clinical pharmacology and therapeutics 2007;81(1):42-9.
2006: George Cusatis; Vanesa Gregorc; Jing Li; Anna Spreafico; Roxann G Ingersoll; Jaap Verweij; Vienna Ludovini; Eugenio Villa; Manuel Hidalgo; Alex Sparreboom; Sharyn D Baker
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Journal of the National Cancer Institute 2006;98(23):1739-42.
2006: Tristan Sissung; Klaus Mross; Seth M Steinberg; Dirk Behringer; William D Figg; Alex Sparreboom; Stephan Mielke
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2893-6.
2006: Floris A de Jong; Diederik F S Kehrer; Ron H J Mathijssen; Geert-Jan Creemers; Peter de Bruijn; Ron van Schaik; A S T Planting; Ate van der Gaast; Ferry A L M Eskens; Jos Th P Janssen; Jan B Ruit; Jaap Verweij; Alex Sparreboom; M J A de Jonge
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
The oncologist 2006;11(8):944-54.
2006: Nehal J Lakhani; Alex Sparreboom; Jürgen Venitz; William L Dahut; William D Figg
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anti-cancer drugs 2006;17(8):977-83.
2006: Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin C Ryan; Ivana Gojo; Jürgen Venitz; William D Figg; Alex Sparreboom
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
2006: Michael C Cox; Jennifer Low; James Lee; Janice M Walshe; Neelima Denduluri; Arlene Berman; Matthew G Permenter; William P Petros; Douglas K Price; William D Figg; Alex Sparreboom; Sandra M Swain
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4636-40.
2006: Erin R Gardner; Herman Burger; Ron van Schaik; Allan T van Oosterom; Ernst A de Bruijn; Gunther Guetens; Hans Prenen; Floris A de Jong; Sharyn D Baker; Susan E Bates; William D Figg; Jaap Verweij; Alex Sparreboom; Kees Nooter
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
2006: Sylvia S W Ng; Alex Sparreboom; Yuval Shaked; Christina Lee; Shan Man; Neil Desai; Patrick Soon-Shiong; William D Figg; Robert S Kerbel
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4331-8.
2006: Sharyn D Baker; Alex Sparreboom
Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2412-3.
2006: Charity D Scripture; William D Figg; Alex Sparreboom
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.
Current neuropharmacology 2006;4(2):165-72.
2006: Alex Sparreboom; William D Figg
Identifying sources of interindividual pharmacokinetic variability with population modeling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1951-3.
2006: Walter J Loos; Felix E de Jongh; Alex Sparreboom; Ronald de Wit; Desirée M van Boven-van Zomeren; Gerrit Stoter; Kees Nooter; Jaap Verweij
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1499-506.
2006: Tristan Sissung; Douglas K Price; Alex Sparreboom; William D Figg
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Molecular cancer research : MCR 2006;4(3):135-50.
2006: Nicola F Smith; William D Figg; Alex Sparreboom
Pharmacogenetics of irinotecan metabolism and transport: an update.
Toxicology in vitro : an international journal published in association with BIBRA 2006;20(2):163-75.
2006: Charity D Scripture; William D Figg; Alex Sparreboom
The role of drug-metabolising enzymes in clinical responses to chemotherapy.
Expert opinion on drug metabolism & toxicology 2006;2(1):17-25.
2006: Milin R Acharya; Alex Sparreboom; Edward A Sausville; BA Conley; James Doroshow; Jürgen Venitz; William D Figg
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
2006: Kyunghwa Hwang; Charity D Scripture; Martin Gutierrez; Shivaani Kummar; William D Figg; Alex Sparreboom
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;830(1):35-40.
2006: Erin R Gardner; Chi-Ting Liau; Zyting E Chu; William D Figg; Alex Sparreboom
Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(14):2170-4.
2006: Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Clinical pharmacokinetics of docetaxel : recent developments.
Clinical pharmacokinetics 2006;45(3):235-52.
2006: William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herb Kotz; Debbie McNally; Allyson L Parr; Diana Nguyen; Sherry X Yang; Seth M Steinberg; Jürgen Venitz; Alex Sparreboom; William D Figg
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer biology & therapy 2006;5(1):22-7.
2006: Stephan Mielke; Alex Sparreboom; Klaus Mross
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
European journal of cancer (Oxford, England : 1990) 2006;42(1):24-30.
2005: Anja Henningsson; Sharon Marsh; Walter J Loos; Mats O Karlsson; Adam Garsa; Klaus Mross; Stephan Mielke; Lucia Viganò; Alberta Locatelli; Jaap Verweij; Alex Sparreboom; howard mcleod
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8097-104.
2005: Stephan Mielke; Alex Sparreboom; Dirk Behringer; Klaus Mross
Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen.
Anticancer research 2005;25(6C):4423-7.
2005: Nielka P H van Erp; Sharyn D Baker; Ming Zhao; MICHELLE RUDEK-RENAUT; Henk-Jan Guchelaar; J W R Nortier; Alex Sparreboom; Hans Gelderblom
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7800-6.
2005: Alex Sparreboom; Sharyn D Baker; Jaap Verweij
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7765-7.
2005: Erin R Lepper; Sharyn D Baker; Matthew G Permenter; Nicole Ries; Ron van Schaik; Paul W Schenk; Douglas K Price; Danielle Ahn; Nicola F Smith; George Cusatis; Roxann G Ingersoll; Susan E Bates; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7398-404.
2005: Nicola F Smith; William D Figg; Alex Sparreboom
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
Expert opinion on drug metabolism & toxicology 2005;1(3):429-45.
2005: Charity D Scripture; Alex Sparreboom; William D Figg
Modulation of cytochrome P450 activity: implications for cancer therapy.
The lancet oncology 2005;6(10):780-9.
2005: Edwin M Posadas; James L Gulley; Philip M Arlen; Alisa Trout; Howard L Parnes; John Wright; Min-Jung Lee; Eun Joo Chung; Jane Trepel; Alex Sparreboom; Clara Chen; Elizabeth Jones; Seth M Steinberg; Andrew Daniels; William D Figg; William L Dahut
A phase II study of perifosine in androgen independent prostate cancer.
Cancer biology & therapy 2005;4(10):1133-7.
2005: Milin R Acharya; Alex Sparreboom; Jürgen Venitz; William D Figg
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Molecular pharmacology 2005;68(4):917-32.
2005: Nicola F Smith; Milin R Acharya; Neil Desai; William D Figg; Alex Sparreboom
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
Cancer biology & therapy 2005;4(8):815-8.
2005: Frederike K Engels; Alex Sparreboom; Ron A A Mathot; Jaap Verweij
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
British journal of cancer 2005;93(2):173-7.
2005: Stephan Mielke; Alex Sparreboom; Seth M Steinberg; Hans Gelderblom; Clemens Unger; Dirk Behringer; Klaus Mross
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4843-50.
2005: Herman Burger; Hans Van Tol; Mariël Brok; Erik A C Wiemer; Ernst A de Bruijn; Gunther Guetens; Gert de Boeck; Alex Sparreboom; Jaap Verweij; Kees Nooter
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Cancer biology & therapy 2005;4(7):747-52.
2005: Qin C Ryan; Donna Headlee; Milin R Acharya; Alex Sparreboom; Jane Trepel; Joseph Ye; William D Figg; Kyunghwa Hwang; Eun Joo Chung; Anthony J Murgo; Giovanni Melillo; Yusri Elsayed; Manish Monga; Mikhail Kalnitskiy; James Zwiebel; Edward A Sausville
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
2005: Charity D Scripture; William D Figg; Alex Sparreboom
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
Therapeutics and clinical risk management 2005;1(2):107-14.
2005: Alex Sparreboom
BSA-based dosing and alternative approaches.
Clinical advances in hematology & oncology : H&O 2005;3(6):448-50.
2005: Alex Sparreboom; Charity D Scripture; Vuong Trieu; Paul J Williams; Tapas De; Andrew Yang; Bridget Beals; William D Figg; Michael Hawkins; Neil Desai
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4136-43.
2005: Alex Sparreboom; Walter J Loos; Herman Burger; Tristan Sissung; Jaap Verweij; William D Figg; Kees Nooter; Hans Gelderblom
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
2005: Charity D Scripture; Janos Szebeni; Walter J Loos; William D Figg; Alex Sparreboom
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer biology & therapy 2005;4(5):555-60.
2005: Floris A de Jong; Frederike K Engels; Ron H J Mathijssen; Lia van Zuylen; Jaap Verweij; Remco P H Peters; Alex Sparreboom
Medicinal cannabis in oncology practice: still a bridge too far?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2886-91.
2005: Qingyu Zhou; Alex Sparreboom; Eng Huat Tan; Yin Bun Cheung; Ann Lee; Donald Poon; Edmund J D Lee; Balram Chowbay
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
British journal of clinical pharmacology 2005;59(4):415-24.
2005: Eiichi Fuse; Takashi Kuwabara; Alex Sparreboom; Edward A Sausville; William D Figg
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Journal of clinical pharmacology 2005;45(4):394-403.
2005: Erin R Lepper; Kees Nooter; Jaap Verweij; Milin R Acharya; William D Figg; Alex Sparreboom
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Pharmacogenomics 2005;6(2):115-38.
2005: Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Floris A de Jong; M J A de Jonge; José Thomas; Ferry A L M Eskens; Ron van Schaik; Johan Selleslach; Judith ter Steeg; Patricia Lefebvre; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; Allan T van Oosterom
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1504-11.
2005: Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Dorothee Semiond; Maja J A deJonge; Ferry A L M Eskens; Judith ter Steeg; Johan Selleslach; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; Allan T van Oosterom
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):889-98.
2005: Otto Soepenberg; M J A de Jonge; Alex Sparreboom; Peter de Bruin; Ferry A L M Eskens; Gerda de Heus; Jantien Wanders; Peter Cheverton; Murray P Ducharme; Jaap Verweij
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):703-11.
2005: Nehal J Lakhani; Erin R Lepper; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(9):1176-82.
2005: Johanna E A Portielje; Wim H J Kruit; Anke J M Eerenberg; Martin Schuler; Alex Sparreboom; Cor H J Lamers; Jan W Gratama; Gerrit Stoter; Christoph Huber; C Erik Hack
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Cancer immunology, immunotherapy : CII 2005;54(1):37-43.
2005: Sharyn D Baker; Jing Li; Albert J ten Tije; William D Figg; Wilfried J Graveland; Jaap Verweij; Alex Sparreboom
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clinical pharmacology and therapeutics 2005;77(1):43-53.
2005: A S T Planting; Pieter Sonneveld; Ate van der Gaast; Alex Sparreboom; M E L van der Burg; G P M Luyten; K de Leeuw; MM de Boer-Dennert; Paul Wissel; Roxanne C Jewell; Elaine M Paul; N B Purvis; Jaap Verweij
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(1):91-9.
2004: Sharyn D Baker; Ron van Schaik; Laurent P Rivory; Albert J ten Tije; Kimberly Dinh; Wilfried J Graveland; Paul W Schenk; Kellie A Charles; Stephen J Clarke; Michael A Carducci; William P McGuire; Fitzroy W Dawkins; Hans Gelderblom; Jaap Verweij; Alex Sparreboom
Factors affecting cytochrome P-450 3A activity in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8341-50.
2004: Frédéric Léger; Walter J Loos; Roland Bugat; Ron H J Mathijssen; Marine Goffinet; Jaap Verweij; Alex Sparreboom; Etienne Chatelut
Mechanism-based models for topotecan-induced neutropenia.
Clinical pharmacology and therapeutics 2004;76(6):567-78.
2004: Tanyifor M Tohnya; Kyunghwa Hwang; Erin R Lepper; Howard A Fine; William L Dahut; Jürgen Venitz; Alex Sparreboom; William D Figg
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):135-41.
2004: Ron H J Mathijssen; Floris A de Jong; Ron van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
2004: Alex Sparreboom; Huachen Chen; Milin R Acharya; Adrian M Senderowicz; Richard A Messmann; Takashi Kuwabara; David J Venzon; Anthony J Murgo; Donna Headlee; Edward A Sausville; William D Figg
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
2004: Kyunghwa Hwang; Richard L Piekarz; Susan E Bates; William D Figg; Alex Sparreboom
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(1):81-6.
2004: Floris A de Jong; Sharon Marsh; Ron H J Mathijssen; Cristi King; Jaap Verweij; Alex Sparreboom; howard mcleod
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5889-94.
2004: Antoinette R Tan; Xiaowei Yang; Arlene Berman; Suoping Zhai; Alex Sparreboom; Allyson L Parr; Catherine Chow; Jaime Brahim; Seth M Steinberg; William D Figg; Sandra M Swain
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5038-47.
2004: Luca Paoluzzi; Arun S Singh; Douglas K Price; Romano Danesi; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Journal of clinical pharmacology 2004;44(8):854-60.
2004: Antoinette R Tan; Xiaowei Yang; Stephen M Hewitt; Arlene Berman; Erin R Lepper; Alex Sparreboom; Allyson L Parr; William D Figg; Catherine Chow; Seth M Steinberg; Stephen L Bacharach; Millie Whatley; Jorge Carrasquillo; Jaime Brahim; Seth A Ettenberg; Stan Lipkowitz; Sandra M Swain
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3080-90.
2004: Albert J ten Tije; Walter J Loos; Ming Zhao; Sharyn D Baker; Roelien H Enting; Hans van der Meulen; Jaap Verweij; Alex Sparreboom
Limited cerebrospinal fluid penetration of docetaxel.
Anti-cancer drugs 2004;15(7):715-8.
2004: Milin R Acharya; Sharyn D Baker; Jaap Verweij; William D Figg; Alex Sparreboom
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Analytical biochemistry 2004;331(1):192-4.
2004: Felix E de Jongh; James M Gallo; Meiyu Shen; Jaap Verweij; Alex Sparreboom
Population pharmacokinetics of cisplatin in adult cancer patients.
Cancer chemotherapy and pharmacology 2004;54(2):105-12.
2004: Alex Sparreboom; Sharon Marsh; Ron H J Mathijssen; Jaap Verweij; howard mcleod
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.
Investigational new drugs 2004;22(3):285-9.
2004: Erin R Lepper; J Kevin Hicks; Jaap Verweij; Suoping Zhai; William D Figg; Alex Sparreboom
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):305-10.
2004: Nehal J Lakhani; Alex Sparreboom; William L Dahut; Jürgen Venitz; William D Figg
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):289-93.
2004: Alex Sparreboom; Hans Gelderblom; Sharon Marsh; Ranjeet Ahluwalia; Rosendo Obach; Paola Principe; Chris Twelves; Jaap Verweij; howard mcleod
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Clinical pharmacology and therapeutics 2004;76(1):38-44.
2004: Floris A de Jong; Ron H J Mathijssen; Rujia Xie; Jaap Verweij; Alex Sparreboom
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4068-71.
2004: Alex Sparreboom; Michael C Cox; Milin R Acharya; William D Figg
Herbal remedies in the United States: potential adverse interactions with anticancer agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2489-503.
2004: Tanyifor M Tohnya; Sonia Kim; Howard A Fine; Lara Dunn; William D Figg; Alex Sparreboom
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;805(1):135-40.
2004: Milin R Acharya; Jürgen Venitz; William D Figg; Alex Sparreboom
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004;7(3):195-208.
2004: Kyunghwa Hwang; Milin R Acharya; Edward A Sausville; Suoping Zhai; Eunhee W Woo; Jürgen Venitz; William D Figg; Alex Sparreboom
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
2004: Frederike K Engels; Albert J ten Tije; Sharyn D Baker; Carlton K K Lee; Walter J Loos; Arnold G Vulto; Jaap Verweij; Alex Sparreboom
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clinical pharmacology and therapeutics 2004;75(5):448-54.
2004: MICHELLE RUDEK-RENAUT; Alex Sparreboom; Elizabeth Garrett-Mayer; Deborah K Armstrong; Antonio C Wolff; Jaap Verweij; Sharyn D Baker
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1170-8.
2004: Peter de Bruijn; Edwin W Willems; Walter J Loos; Jaap Verweij; Alex Sparreboom
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Analytical biochemistry 2004;328(1):84-6.
2004: Alex Sparreboom; Diederik F S Kehrer; Ron H J Mathijssen; R Xie; M J A de Jonge; Peter de Bruijn; A S T Planting; Ferry A L M Eskens; Coleta Verheij; Gerda de Heus; A Klaren; S Zhang; Tom Verhaeghe; Peter A Palmer; Jaap Verweij
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
British journal of cancer 2004;90(8):1508-15.
2004: Sharyn D Baker; Ming Zhao; Carlton K K Lee; Jaap Verweij; Yelena Zabelina; Julie R Brahmer; Antonio C Wolff; Alex Sparreboom; Michael A Carducci
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1976-83.
2004: Lia van Zuylen; John Bridgewater; Alex Sparreboom; Ferry A L M Eskens; Peter de Bruijn; Ivo Sklenar; A S T Planting; Les Choi; Douglas Bootle; Christian Mueller; Jonathan A Ledermann; Jaap Verweij
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1949-55.
2004: Marco B Polee; Alex Sparreboom; Ferry A L M Eskens; Ronald Hoekstra; Jacqueline van de Schaaf; Jaap Verweij; Gerrit Stoter; Ate van der Gaast
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1928-34.
2004: Otto Soepenberg; Alex Sparreboom; M J A de Jonge; A S T Planting; Gerda de Heus; Walter J Loos; C M Hartman; C Bowden; Jaap Verweij
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(5):681-8.
2004: Sylvia S W Ng; William D Figg; Alex Sparreboom
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Cancer research 2004;64(3):821-4.
2004: Albert J ten Tije; Carolien H Smorenburg; Caroline Seynaeve; Alex Sparreboom; Kristel L Schothorst; Leon G M Kerkhofs; L G P M van Reisen; Gerrit Stoter; Marijke Bontenbal; Jaap Verweij
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
European journal of cancer (Oxford, England : 1990) 2004;40(3):352-7.
2004: Frédéric Léger; W J Loos; J Fourcade; Roland Bugat; M Goffinet; Ron H J Mathijssen; J Verweij; Alex Sparreboom; Etienne Chatelut
Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.
British journal of cancer 2004;90(2):343-7.
2004: Sharyn D Baker; Ming Zhao; Ping He; Michael A Carducci; Jaap Verweij; Alex Sparreboom
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.
Analytical biochemistry 2004;324(2):276-84.
2004: Otto Soepenberg; Peter de Bruijn; Jaap Verweij; Ryo Atsumi; Alex Sparreboom
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(1):15-22.
2003: Michael E Franks; Gordon R Macpherson; Erin R Lepper; William D Figg; Alex Sparreboom
New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(6):301-12.
2003: Nehal J Lakhani; Jürgen Venitz; William D Figg; Alex Sparreboom
Pharmacogenetics of estrogen metabolism and transport in relation to cancer.
Current drug metabolism 2003;4(6):505-13.
2003: Albert J ten Tije; Walter J Loos; Jaap Verweij; Sharyn D Baker; Kimberly Dinh; William D Figg; Alex Sparreboom
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
2003: Erin R Lepper; Sandra M Swain; Antoinette R Tan; William D Figg; Alex Sparreboom
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):181-8.
2003: Floris A de Jong; Ron H J Mathijssen; Peter de Bruijn; Walter J Loos; Jaap Verweij; Alex Sparreboom
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;795(2):383-8.
2003: Walter J Loos; Sharyn D Baker; Jaap Verweij; Joke G Boonstra; Alex Sparreboom
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Clinical pharmacology and therapeutics 2003;74(4):364-71.
2003: Ron H J Mathijssen; Sharon Marsh; Mats O Karlsson; Rujia Xie; Sharyn D Baker; Jaap Verweij; Alex Sparreboom; howard mcleod
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3246-53.
2003: Albert J ten Tije; Timothy W Synold; Darcy Spicer; Jaap Verweij; James Doroshow; Alex Sparreboom
Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
Investigational new drugs 2003;21(3):291-8.
2003: Albert J ten Tije; Jaap Verweij; Alex Sparreboom; Ate van der Gaast; Camilla Fowst; francesco Fiorentini; Jennifer Tursi; Alessandro Antonellini; Marijke Mantel; Carla M Hartman; Gerrit Stoter; A S T Planting; M J A de Jonge
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2957-64.
2003: Alex Sparreboom; Jaap Verweij
Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2803-4; author reply 2805-6.
2003: Hans Gelderblom; Walter J Loos; Alex Sparreboom; Otto Soepenberg; M J A de Jonge; Desirée M van Boven-van Zomeren; Jaap Verweij
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.
European journal of cancer (Oxford, England : 1990) 2003;39(11):1542-6.
2003: Hans Gelderblom; Sharyn D Baker; Ming Zhao; Jaap Verweij; Alex Sparreboom
Distribution of paclitaxel in plasma and cerebrospinal fluid.
Anti-cancer drugs 2003;14(5):365-8.
2003: Anja Henningsson; Alex Sparreboom; Marie Sandström; Agneta Freijs; Rolf Larsson; Jonas Bergh; Peter Nygren; Mats O Karlsson
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1105-14.
2003: Alex Sparreboom; Romano Danesi; Yuichi Ando; Juliana Chan; William D Figg
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(2):71-84.
2003: Walter J Loos; Hans Gelderblom; Jaap Verweij; Desirée M van Boven-van Zomeren; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Anti-cancer drugs 2003;14(3):227-32.
2003: Carolien H Smorenburg; Alex Sparreboom; Marijke Bontenbal; Gerrit Stoter; Kees Nooter; Jaap Verweij
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):197-202.
2003: Otto Soepenberg; Alex Sparreboom; Jaap Verweij
Clinical studies of camptothecin and derivatives.
The Alkaloids. Chemistry and biology 2003;60():1-50.
2003: Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Clinical pharmacokinetics 2003;42(7):665-85.
2003: Alex Sparreboom; Antonio C Wolff; Jaap Verweij; Yelena Zabelina; Desirée M van Zomeren; Gregory L McIntire; Charles S Swindell; Ross C Donehower; Sharyn D Baker
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):151-9.
2003: Johanna E A Portielje; Cor H J Lamers; Wim H J Kruit; Alex Sparreboom; Reinder L H Bolhuis; Gerrit Stoter; Christoph Huber; Jan W Gratama
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):76-83.
2003: Carolien H Smorenburg; Albert J ten Tije; Jaap Verweij; Marijke Bontenbal; Klaus Mross; Desirée M van Zomeren; Caroline Seynaeve; Alex Sparreboom
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(2):196-202.
2002: Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B. Grochow; Alex Sparreboom
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Journal of the National Cancer Institute 2002;94(24):1883-8.
2002: Felix E de Jongh; Ronald de Wit; Jaap Verweij; Alex Sparreboom; Martin J van den Bent; Gerrit Stoter; M E L van der Burg
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(15):2005-13.
2002: Rujia Xie; Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij; Mats O Karlsson
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Clinical pharmacology and therapeutics 2002;72(3):265-75.
2002: A Felici; Jaap Verweij; Alex Sparreboom
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
European journal of cancer (Oxford, England : 1990) 2002;38(13):1677-84.
2002: Ron H J Mathijssen; Jaap Verweij; Peter de Bruijn; Walter J Loos; Alex Sparreboom
Effects of St. John's wort on irinotecan metabolism.
Journal of the National Cancer Institute 2002;94(16):1247-9.
2002: Walter J Loos; Janos Szebeni; Albert J ten Tije; Jaap Verweij; Desirée M van Zomeren; Kyu-nung Chung; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
Anti-cancer drugs 2002;13(7):767-75.
2002: Rujia Xie; Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij; Mats O Karlsson
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3293-301.
2002: Diederik F S Kehrer; Ron H J Mathijssen; Jaap Verweij; Peter de Bruijn; Alex Sparreboom
Modulation of irinotecan metabolism by ketoconazole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3122-9.
2002: Ron H J Mathijssen; Jaap Verweij; Walter J Loos; Peter de Bruijn; Kees Nooter; Alex Sparreboom
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
British journal of cancer 2002;87(2):144-50.
2002: Alex Sparreboom; Ming Zhao; Julie R Brahmer; Jaap Verweij; Sharyn D Baker
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;773(2):183-90.
2002: Ron H J Mathijssen; Walter J Loos; Jaap Verweij; Alex Sparreboom
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Current cancer drug targets 2002;2(2):103-23.
2002: Lia van Zuylen; Alex Sparreboom; Ate van der Gaast; Kees Nooter; Ferry A L M Eskens; E Brouwer; CJ Bol; R de Vries; Peter A Palmer; Jaap Verweij
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1090-9.
2002: Hans Gelderblom; Jaap Verweij; Desirée M van Zomeren; Dirk Buijs; Linda Ouwens; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1237-41.
2002: M J A de Jonge; Cornelis J A Punt; Alex Sparreboom; A S T Planting; M E W J Peters; Jacqueline van De Schraaf; Ann Jackman; Rob Smith; P H M De Mulder; Jaap Verweij
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1923-31.
2002: Walter J Loos; Jaap Verweij; Diederik F S Kehrer; Peter de Bruijn; Franciscus M H de Groot; Marta Hamilton; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):856-62.
2002: M Louwerens; Carolien H Smorenburg; Alex Sparreboom; Walter J Loos; Jaap Verweij; Ronald de Wit
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(4):497-504.
2002: Diederik F S Kehrer; Annelies M Bos; Jaap Verweij; Harry J Groen; Walter J Loos; Alex Sparreboom; M J A de Jonge; Marta Hamilton; Terri Cameron; Elisabeth G E de Vries
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1222-31.
2002: Ron H J Mathijssen; Alex Sparreboom; Herlinde Dumez; Allan T van Oosterom; Ernst A de Bruijn
Altered irinotecan metabolism in a patient receiving phenytoin.
Anti-cancer drugs 2002;13(2):139-40.
2002: Hans Gelderblom; Klaus Mross; Albert J ten Tije; Dirk Behringer; Stephan Mielke; Desirée M van Zomeren; Jaap Verweij; Alex Sparreboom
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):574-81.
2002: Walter J Loos; Desirée M van Zomeren; Hans Gelderblom; Jaap Verweij; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;766(1):99-105.
2002: Ryo Okamoto; Hiroshi Takano; Tatsunori Okamura; Ji-Seon Park; Keiji Tanimoto; Takashi Sekikawa; Wataru Yamamoto; Alex Sparreboom; Jaap Verweij; Masahiko Nishiyama
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Japanese journal of cancer research : Gann 2002;93(1):93-102.
2002: Ron H J Mathijssen; Jaap Verweij; M J A de Jonge; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):81-7.
2002: Hans Gelderblom; Walter J Loos; Jaap Verweij; M E L van der Burg; M J A de Jonge; E Brouwer; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):205-13.
2002: Alex Sparreboom; M J A de Jonge; Jaap Verweij
The use of oral cytotoxic and cytostatic drugs in cancer treatment.
European journal of cancer (Oxford, England : 1990) 2002;38(1):18-22.
2001: Carolien H Smorenburg; Alex Sparreboom; Marijke Bontenbal; Jaap Verweij
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2310-23.
2001: Hans Gelderblom; Alex Sparreboom; M J A de Jonge; Walter J Loos; E Wilms; Marijke Mantel; B Hennis; I Camlett; Jaap Verweij; M E L van der Burg
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
British journal of cancer 2001;85(8):1124-9.
2001: Ronald de Wit; A C de Boer; G H vd Linden; G Stoter; Alex Sparreboom; J Verweij
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.
British journal of cancer 2001;85(8):1099-101.
2001: Anja Henningsson; Mats O Karlsson; L Viganò; Luca Gianni; Jaap Verweij; Alex Sparreboom
Mechanism-based pharmacokinetic model for paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(20):4065-73.
2001: Alex Sparreboom; K Nooter; W J Loos; J Verweij
The (ir)relevance of plasma protein binding of anticancer drugs.
The Netherlands journal of medicine 2001;59(4):196-207.
2001: Felix E de Jongh; Jaap Verweij; Walter J Loos; Ronald de Wit; M J A de Jonge; A S T Planting; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3733-9.
2001: Hans Gelderblom; Jaap Verweij; Kees Nooter; Alex Sparreboom
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1590-8.
2001: Ron H J Mathijssen; RJ van Alphen; Jaap Verweij; Walter J Loos; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2182-94.
2001: W Yamamoto; Jaap Verweij; Peter de Bruijn; M J A de Jonge; H Takano; M Nishiyama; M Kurihara; Alex Sparreboom
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Anti-cancer drugs 2001;12(5):419-32.
2001: Lia van Zuylen; Jaap Verweij; Alex Sparreboom
Role of formulation vehicles in taxane pharmacology.
Investigational new drugs 2001;19(2):125-41.
2001: Diederik F S Kehrer; Alex Sparreboom; Jaap Verweij; Peter de Bruijn; C A Nierop; J van de Schraaf; E J Ruijgrok; M J A de Jonge
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1136-41.
2001: Peter de Bruijn; Diederik F S Kehrer; Jaap Verweij; Alex Sparreboom
Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism.
Journal of chromatography. B, Biomedical sciences and applications 2001;753(2):395-400.
2001: Lia van Zuylen; M O Karlsson; Jaap Verweij; E Brouwer; Peter de Bruijn; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
Cancer chemotherapy and pharmacology 2001;47(4):309-18.
2001: Ferry A L M Eskens; A Awada; David L Cutler; M J A de Jonge; G P Luyten; M N Faber; Paul Statkevich; Alex Sparreboom; Jaap Verweij; Axel R Hanauske; Martine Piccart
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1167-75.
2001: Diederik F S Kehrer; Otto Soepenberg; Walter J Loos; Jaap Verweij; Alex Sparreboom
Modulation of camptothecin analogs in the treatment of cancer: a review.
Anti-cancer drugs 2001;12(2):89-105.
2001: Johanna E A Portielje; Wim H J Kruit; Anke J M Eerenberg; M Schuler; Alex Sparreboom; C H Lamers; Reinder L H Bolhuis; Gerrit Stoter; Christoph Huber; C Erik Hack
Interleukin 12 induces activation of fibrinolysis and coagulation in humans.
British journal of haematology 2001;112(2):499-505.
2000: Walter J Loos; H J Gelderblom; Jaap Verweij; E Brouwer; M J A de Jonge; Alex Sparreboom
Gender-dependent pharmacokinetics of topotecan in adult patients.
Anti-cancer drugs 2000;11(9):673-80.
2000: E Brouwer; Jaap Verweij; Peter de Bruijn; Walter J Loos; M Pillay; Dirk Buijs; Alex Sparreboom
Measurement of fraction unbound paclitaxel in human plasma.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1141-5.
2000: A J Gelderblom; Walter J Loos; M J A de Jonge; Alex Sparreboom; A S T Planting; M E L van der Burg; E Brouwer; Coleta Verheij; L Ouwens; Solange Hearn; Jaap Verweij
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1205-7.
2000: Diederik F S Kehrer; W Yamamoto; Jaap Verweij; M J A de Jonge; Peter de Bruijn; Alex Sparreboom
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3451-8.
2000: Lia van Zuylen; Kees Nooter; Alex Sparreboom; Jaap Verweij
Development of multidrug-resistance convertors: sense or nonsense?
Investigational new drugs 2000;18(3):205-20.
2000: Walter J Loos; Hans Gelderblom; Alex Sparreboom; Jaap Verweij; M J A de Jonge
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2685-9.
2000: Lia van Zuylen; Jaap Verweij; Kees Nooter; E Brouwer; Gerrit Stoter; Alex Sparreboom
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2598-603.
2000: LC Pronk; P Vasey; Alex Sparreboom; Bruno Reigner; A S T Planting; RJ Gordon; B Osterwalder; Jaap Verweij; Chris Twelves
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
British journal of cancer 2000;83(1):22-9.
2000: Lia van Zuylen; Luca Gianni; Jaap Verweij; Klaus Mross; E Brouwer; Walter J Loos; Alex Sparreboom
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Anti-cancer drugs 2000;11(5):331-7.
2000: Walter J Loos; Peter de Bruijn; Jaap Verweij; Alex Sparreboom
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Anti-cancer drugs 2000;11(5):315-24.
2000: M J A de Jonge; Walter J Loos; Hans Gelderblom; A S T Planting; M E L van der Burg; Alex Sparreboom; E Brouwer; V van Beurden; Marijke Mantel; E Doyle; Solange Hearn; G Ross; Jaap Verweij
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2104-15.
2000: Lia van Zuylen; Alex Sparreboom; Ate van der Gaast; M E L van der Burg; V van Beurden; CJ Bol; R Woestenborghs; Peter A Palmer; Jaap Verweij
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1365-71.
2000: Hans Gelderblom; Walter J Loos; Jaap Verweij; M J A de Jonge; Alex Sparreboom
Topotecan lacks third space sequestration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1288-92.
2000: Ferry A L M Eskens; Nicola C Levitt; Alex Sparreboom; Les Choi; R Mather; Jaap Verweij; Adrian L Harris
Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):431-3.
2000: Walter J Loos; Diederik F S Kehrer; E Brouwer; Jaap Verweij; Peter de Bruijn; Marta Hamilton; S Gill; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(1):155-63.
2000: M J A de Jonge; Jaap Verweij; Peter de Bruijn; E Brouwer; Ron H J Mathijssen; RJ van Alphen; MM de Boer-Dennert; Laurent Vernillet; Christian Jacques; Alex Sparreboom
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):195-203.
2000: M J A de Jonge; Alex Sparreboom; A S T Planting; M E L van der Burg; MM de Boer-Dennert; Judith ter Steeg; Christian Jacques; Jaap Verweij
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):187-94.
1999: Walter J Loos; Peter de Bruijn; Lia van Zuylen; Jaap Verweij; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(2):293-7.
1999: Alex Sparreboom; Walter J Loos; Kees Nooter; Gerrit Stoter; Jaap Verweij
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(1):111-9.
1999: Hans Gelderblom; Jaap Verweij; E Brouwer; M Pillay; Peter de Bruijn; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(11):1300-5.
1999: Olaf van Tellingen; Jos H Beijnen; Jaap Verweij; E J Scherrenburg; Willem Nooijen; Alex Sparreboom
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: Alex Sparreboom; A S T Planting; Roxanne C Jewell; M E L van der Burg; Ate van der Gaast; Peter de Bruijn; Walter J Loos; Kees Nooter; L H Chandler; Elaine M Paul; Paul Wissel; Jaap Verweij
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Anti-cancer drugs 1999;10(8):719-28.
1999: Walter J Loos; Jaap Verweij; H J Gelderblom; M J A de Jonge; E Brouwer; BK Dallaire; Alex Sparreboom
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.
Anti-cancer drugs 1999;10(8):705-10.
1999: M J A de Jonge; Jaap Verweij; A S T Planting; M E L van der Burg; Gerrit Stoter; MM de Boer-Dennert; Peter de Bruijn; E Brouwer; Laurent Vernillet; Alex Sparreboom
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2012-7.
1999: M J A de Jonge; Cornelis J A Punt; A H Gelderblom; Walter J Loos; V van Beurden; A S T Planting; M E L van der Burg; Lydia Van Maanen; BK Dallaire; Jaap Verweij; D J Wagener; Alex Sparreboom
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2219-26.
1999: Alex Sparreboom; M J A de Jonge; C J Punt; Walter J Loos; Kees Nooter; Gerrit Stoter; M G Porro; Jaap Verweij
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(7):816-20.
1999: M J A de Jonge; Jaap Verweij; Walter J Loos; BK Dallaire; Alex Sparreboom
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Clinical pharmacology and therapeutics 1999;65(5):491-9.
1999: Peter de Bruijn; M J de Jonge; J Verweij; W J Loos; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.
Analytical biochemistry 1999;269(1):174-8.
1999: Alex Sparreboom; Lia van Zuylen; E Brouwer; Walter J Loos; Peter de Bruijn; Hans Gelderblom; M Pillay; Kees Nooter; Gerrit Stoter; Jaap Verweij
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Cancer research 1999;59(7):1454-7.
1999: Peter de Bruijn; Jaap Verweij; Walter J Loos; HJ Kolker; A S T Planting; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
Analytical biochemistry 1999;266(2):216-21.
1999: Jaap Verweij; Alex Sparreboom; K Nooter
Mitomycins.
Cancer chemotherapy and biological response modifiers 1999;18():46-58.
1999: H A Gelderblom; M J A de Jonge; Alex Sparreboom; Jaap Verweij
Oral topoisomerase 1 inhibitors in adult patients: present and future.
Investigational new drugs 1999;17(4):401-15.
1999: Ron H J Mathijssen; RJ van Alphen; M J A de Jonge; Jaap Verweij; Peter de Bruijn; Walter J Loos; Kees Nooter; Laurent Vernillet; Gerrit Stoter; Alex Sparreboom
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Anti-cancer drugs 1999;10(1):9-16.
1998: Alex Sparreboom; M J A de Jonge; Peter de Bruijn; E Brouwer; Kees Nooter; Walter J Loos; RJ van Alphen; Ron H J Mathijssen; Gerrit Stoter; Jaap Verweij
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2747-54.
1998: Alex Sparreboom; Peter de Bruijn; M J A de Jonge; Walter J Loos; Gerrit Stoter; Jaap Verweij; Kees Nooter
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):225-35.
1998: Alex Sparreboom; Jaap Verweij; M E L van der Burg; Walter J Loos; E Brouwer; L Viganò; A Locatelli; AI de Vos; Kees Nooter; Gerrit Stoter; Luca Gianni
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1937-42.
1998: Alex Sparreboom; M J A de Jonge; Cornelis J A Punt; Kees Nooter; Walter J Loos; M G Porro; Jaap Verweij
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1915-9.
1998: E Brouwer; Jaap Verweij; B Hauns; Walter J Loos; Kees Nooter; Klaus Mross; Gerrit Stoter; Alex Sparreboom
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Analytical biochemistry 1998;261(2):198-202.
1998: M J A de Jonge; Alex Sparreboom; Jaap Verweij
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Cancer treatment reviews 1998;24(3):205-20.
1998: Alex Sparreboom; Peter de Bruijn; Kees Nooter; Walter J Loos; Gerrit Stoter; Jaap Verweij
Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):159-64.
1998: Alex Sparreboom; Walter J Loos; Jaap Verweij; AI de Vos; M E L van der Burg; Gerrit Stoter; Kees Nooter
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Analytical biochemistry 1998;255(2):171-5.
1998: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; J H Beijnen
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Anti-cancer drugs 1998;9(1):1-17.
1997: AI de Vos; Kees Nooter; Jaap Verweij; Walter J Loos; E Brouwer; Peter de Bruijn; E J Ruijgrok; M E L van der Burg; Gerrit Stoter; Alex Sparreboom
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1145-50.
1997: Peter de Bruijn; Jaap Verweij; Walter J Loos; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):277-85.
1997: Walter J Loos; Alex Sparreboom; Jaap Verweij; Kees Nooter; Gerrit Stoter; J H M Schellens
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
1997: Walter J Loos; Jaap Verweij; Kees Nooter; Gerrit Stoter; Alex Sparreboom
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(2):437-41.
1997: Alex Sparreboom; J van Asperen; U Mayer; Alfred H Schinkel; J W Smit; D K Meijer; Piet Borst; Willem Nooijen; Jos H Beijnen; Olaf van Tellingen
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
1997: J van Asperen; Olaf van Tellingen; Alex Sparreboom; Alfred H Schinkel; Piet Borst; Willem Nooijen; Jos H Beijnen
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
1996: Alex Sparreboom; Olaf van Tellingen; manon huizing; Willem Nooijen; Jos H Beijnen
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
1996: Alex Sparreboom; Olaf van Tellingen; E J Scherrenburg; J J Boesen; manon huizing; Willem Nooijen; C Versluis; J H Beijnen
Isolation, purification and biological activity of major docetaxel metabolites from human feces.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):655-8.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
1995: manon huizing; Alex Sparreboom; Hilde Rosing; Olaf van Tellingen; HERBERT PINEDO; Jos H Beijnen
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;674(2):261-8.
1995: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
1995: Alex Sparreboom; manon huizing; J J Boesen; Willem Nooijen; Olaf van Tellingen; Jos H Beijnen
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
1994: M Shameem; T Imai; Yasushi Yoshigae; Alex Sparreboom; Masaki Otagiri
Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration.
Journal of pharmaceutical sciences 1994;83(12):1754-7.